Life Technologies is a global life sciences company with a heritage of providing the most innovative products and services designed to keep our customers at the leading edge of research. Our instruments and consumables are applied across the entire biological spectrum, including agriculture biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. These reliable and easy-to-use solutions are the tools of choice for scientists who are working to solve our world’s most perplexing challenges in health, the environment, agricultural sustainability and public safety.
The Custom Biotech arm of Roche Diagnostics develops and markets solutions for the biomedical and research industries and provides a wide range of products used in in-process quality control testing as well as Pharma Biotech enzymes for dissociating cells from primary tissues, downstream proteases, and biocatalysts. Roche is setting a new standard for tissue-dissociation enzymes with the introduction of our GMP-quality “mammalian tissue-free” Liberase® Enzyme Blends. Our portfolio contains highly purified collagenase with thermolysin or neutral protease enzyme that offers stem cell researchers the tools for optimizing their stem cell isolation protocols to maximize cell yields, viability, functionality and safety!
Scottish Development International (SDI) is Scotland’s agency for economic development. Scotland’s stem cell and regenerative medicine cluster delivers a ”one-stop” solution for companies developing applications at pre-clinical, clinical or commercial stages of development. This dynamic commercial and academic landscape provides unique solutions across the whole supply chain including cell line supplies, screening, characterization, GMP manufacturing, QA/QC and a range of enabling technologies and other supporting services. Scotland has a proven track record in implementing cell therapy clinical trials using the world class MHRA-accredited GMP ATMP manufacturing facilities for Phase I & II embryonic and adult stem cells. All of this expertise is in close proximity across Scotland with excellent connections to the rest of Europe. This makes Scotland the ideal location for academic research collaborations, stem cell technology research and development, clinical/translational research and cell line manufacturing.
The Cell Therapy Catapult is a centre of excellence for regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy, and a place where businesses can start, and confidently grow. Based in London at Guy’s Hospital, the centre plans to take products into early clinical trials, providing clinical, technical, manufacturing and regulatory expertise and access to the NHS. This exciting initiative is the UK’s response to the translational gap between early-stage research and the later stages of clinical development in regenerative medicine. It is a dynamic new approach to developing products for unmet medical needs. Working with industry, academia, the NHS and Government, the Cell Therapy Catapult will be shaping the UK regenerative medicine landscape.
CBRE Group, Inc. (NYSE:CBG), a Fortune 500 and S&P 500 company headquartered in Los Angeles, is the world’s largest commercial real estate services and investment firm (in terms of 2012 revenue). The Company has approximately 37,000 employees (excluding affiliates), and serves real estate owners, investors and occupiers through more than 300 offices (excluding affiliates) worldwide. CBRE offers strategic advice and execution for property sales and leasing; corporate services; property, facilities and project management; mortgage banking; appraisal and valuation; development services; investment management; and research and consulting.
Founded in 1858, Dohmen is a life science services company dedicated to creating a safer, more effective healthcare supply system. As the trusted partner to more than 600 biopharma and medtech innovators, Dohmen propels start-up, mid-tier and Fortune 500 companies with support services that span the commercialization continuum from pre-approval regulatory consulting to in-home patient services. Privately held and conflict free, Dohmen is uniquely positioned to propel personalized healthcare for life science innovators and individuals.
Fluidigm develops, manufactures, and markets life science systems based on integrated fluidic circuits (IFCs). This technology furthers research by minimizing costs and enhancing sensitivity for applications such as single-cell gene expression, high-throughput SNP genotyping, and next-generation sequencing. Single-cell gene expression profiling has recently emerged as a powerful method to uncover heterogeneity in cell populations. In response to this, Fluidigm has developed a streamlined and automated workflow for capturing and analyzing single cells. The new C1™ Single-Cell AutoPrep System isolates single cells starting with low cell number input.
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is developing novel biotherapeutics derived from its proprietary adult stem cell-based technologies. The company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas – systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions. Mesoblast’s corporate strategy is to leverage proprietary cell-based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin future financial growth through investing in manufacturing operations; and enhance the likelihood of commercial success through strategic partnerships. Mesoblast’s strong cash reserves ($315M) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales.
Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Terumo BCT—Unlocking the Potential of Blood.
Athersys is a biopharmaceutical company that is committed to developing therapeutic products that we believe have best-in-class potential. Our lead product development programs utilize MultiStem®, a patented and proprietary stem cell product that we believe could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological, and inflammatory and immune disease areas, as well as certain other conditions. MultiStem® is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. We are also developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, and certain neurological disorders.
Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2012 sales of $14.2 billion and has approximately 50,800 employees.
BioSpherix will be exhibiting the Xvivo System, world’s first and only barrier isolator optimized for cells. An economical and practical alternative to cleanrooms for cGMP compliant production of human cells for clinical use. Get better contamination control, better process control, better quality control, and better pocketbook control. Stop by the BioSpherix booth at this year’s Stem Cell Meeting on the Mesa.
CellGenix is an international leading manufacturer and supplier of high quality cytokines and serum-free medium for the ex vivo cell culture of DC, T-Cells, NK-Cells, Hematopoietic Stem Cells, MSC, Chondrocytes, ESC and iPS. CellGenix products are used worldwide in clinical trials in academia, commercial trials, production of vaccine and in translation, validation and testing or assay development by biotechnology partners. The manufacturing is in accordance with GMP guidelines and USP <1043>.
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in solid organ and stem cell transplantation, immunology, infectious disease, hematology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.
Cytori Therapeutics is a cell therapy company dedicated primarily to the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. We have a global product development strategy focused on the U.S. cardiovascular disease market. In the U.S. our goal is to bring our cell therapy to market for treatment of chronic ischemic heart failure through Cytori-sponsored clinical development efforts and to develop a treatment for thermal burns combined with radiation injury under a contract from BARDA, a division of the U.S. Department of Health and Human Services.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify and develop strategic relationships. Our conferences, run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, EuroMedtech™, BioEquity Europe, ChinaBio® Partnering Forum, Partnering for Global Impact®, and Biotech Showcase™. EBD Group’s sophisticated web-based partnering service, partneringONE®, also powers numerous third-party events, and partnering360® is the online community of life science executives that enhances dealmaking productivity year round.
Essen BioScience offers in vitro assays, reagents, contract discovery services and instrumentation that target functional measurement of living cells over time. Designed as the first microscope in incubator, the IncuCyte family of live-cell imagers provides an automated tool for conducting time-lapse microscopy, quantitative image analysis and live content imaging. Essen BioScience CellPlayer live-cell assays for the IncuCyte include kinetic, translational and phenotypic assays for Stem Cell Differentiation, Neurite Outgrowth, Angiogenesis, Proliferation, Apoptosis, Cytotoxicity, Invasion, Migration and Reporter Gene Expression.
At Janssen Research & Development, LLC, we are united and energized by one mission—to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies of Johnson & Johnson, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
Medpace is a global full-service Clinical Research Organization (CRO) providing comprehensive development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal, and diabetes. With extensive medical expertise, a renowned regulatory affairs department, and direct global operations in over 40 countries, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined, and standardized trial management.
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a biotechnology company that develops cell therapies derived from human placentas and is the sole manufacturer of these therapies. Pluristem uses its proprietary, three-dimensional (3D) technology platform for the efficient, controlled, mass production of its PLacental eXpanded (PLX) cell therapy product candidates that can be administered without the need for histocompatability matching. PLX cells serve as a biologically controlled drug delivery platform capable of secreting various therapeutic cytokines and other soluble factors in response to environmental signals. Pluristem’s strategy is to make PLX cells available as an intramuscular (IM) therapy for the treatment of a variety of indications that possess, as a common denominator, the inflammatory/ischemic pathophysiologic state. This includes the use of our PLX cell products involving the indications of peripheral artery disease, soft tissue orthopedic injuries, preeclampsia, acute radiation sickness, and the stimulation of hematopoiesis in diseased or injured bone marrow.
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. and Hong Kong.
StemCells, Inc. is a clinical stage, Nasdaq Listed company (STEM) engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s platform technology, consisting of a proprietary highly purified population of human neural stem cells, HuCNS-SC® cells, is currently in development for the treatment of a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in spinal cord injury in Switzerland and Canada, and has reported positive data for the first three patients,who have completed the trial. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer’s disease with funding support from the California Institute of Regenerative Medicine. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand.
TAP Biosystems provides advanced automated systems for cell therapy scale-up and manufacture. At the 2013 Stem Cell Meeting on the Mesa TAP will be showcasing a range of systems including the CellBase CT™ automated cell culture system for ex vivo expansion of autologous cell therapy products. Plus the Cellmate™ system for batch production of cells in rollers bottles and the RAFT™ system for producing biomimetic 3D tissue models in standard plate formats. Staff from TAP will also be available to discuss our collaborative working process to help businesses create new cell therapy scale-up and GMP manufacturing systems.
WuXi AppTec is a global contract service organization for the pharmaceutical, biologics and device/combination product industries. Our FDA-registered, ISO-certified U.S. facilities provide biologics and device companies with a single-source for cell and tissue products by offering a wide range of manufacturing and testing programs featuring expert technical and regulatory guidance. Services include: GMP/GTP manufacturing/aseptic processing, process development, GMP cell banking and cell line characterization, analytical (e.g., flow cytometry) and adventitious agent testing (e.g., sterility, bioburden, mycoplasma and virus detection) for lot release and stability, biodistribution, toxicology, biocompatibility, package integrity testing, shipping and cleaning validations and environmental monitoring.
STEM CELLS Translational Medicine (SCTM), a monthly, peer reviewed journal, provides a forum for prompt publication of original investigative papers, concise reviews, and clinical trial reports. SCTM publishes manuscripts that advance the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of critical investigations closer to accepted best practices. The Journal answers an acknowledged need within the research and clinical communities for comprehensive and cohesive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigations.
TDM Financial is a financial media group powering SECFilings.com, a leading real-time SEC filings alert service and financial publisher. With an exclusive audience of over 600,000 sophisticated investors and original coverage syndicated on premium financial outlets and portals, our clients receive the most credible exposure to build a following of new longer-term investors. Each month, we cultivate these investors into shareholders by keeping them engaged with compelling client content. For instance, our video content services are designed to effectively engage the right investor audiences and extend the impact of conference presentations. We have a long track record in the healthcare sector, with clients like Athersys Inc. (NASDAQ: ATHX) and Galectin Therapeutics Inc. (NASDAQ: GALT) and specific niche portals like BiotechStockTrader.com that attract healthcare investors.
Investors rely on The Life Sciences Report to share promising investment ideas in the biotech/pharmaceutical, diagnostics, and regenerative medicine industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.
- -- Alaine Maxwell, Associate Director, Americas Marketing, Stem Cells and Translational Research, Life Technologies
“Life Technologies has sponsored this meeting since its inception in 2006, and helped it grow into a leading, annual conference for the regenerative medicine community. Whether your goal is to gain exposure to researchers or put your name out in front of C-level executives, sponsoring this meeting has incredible value.”